Rasio utang jangka cendhak marang ekuitas: Omeros (OMER)

This chart of Omeros Corporation (OMER) stock quotes reflects the performance of a company developing MASP-2-based narsoplimab for targeted immune correction in rare thromboses. Revenue is based on the supply of therapies for inflammation and post-transplant pathologies to medical centers. The current figure is 0.00, while the R&D sector is currently revising inhibitor data and steadily advancing early-stage research.

Developing innovative drugs to combat rare inflammatory diseases requires significant operating expenses. The ratio of short-term liabilities to equity measures the proportion of current borrowings within the equity structure, determining the current financial flexibility of Omeros Corporation (OMER). An analysis of the short-term liabilities-to-equity ratio reveals the balance between aggressive expansion and solvency. Low values confirm balance sheet stability, minimizing default risks during long-term molecular research.